

A Simple Synthesis of 2'-Deoxy-3'-Thioinosine and Its Phosphorothioamidite

Qianfu Luo,* Renjun Cheng, Qiu Wang, Shuming Bao

Key Lab for Advanced Materials and Institute of Fine Chemicals, East China University of Science and Technology, Shanghai 200237, P. R. of China

Fax +86(021)64250597; E-mail: luoqf@ecust.edu.cn

Received: 10.07.2012; Accepted after revision: 09.11.2012

Abstract: 5'-O-[[Bis(4-methoxyphenyl)(phenyl)methyl]]-2'-deoxy-3'-thioinosine and its *S*-phosphorothioamidite were prepared in five and six steps, respectively, from commercially available 2'-deoxyinosine. The key 3'-thio intermediate was synthesized by two sequential configuration inversions: a one-pot oxidation/reduction reaction and an S_N2 reaction. This intermediate was readily converted into the target compound with a high yield. Compared with other methods, this synthetic strategy has the advantages of brief reaction steps, a relatively high overall yield, and regioselectivity for the configuration inversions. The products might be useful as intermediates for the preparation of new functionalized nucleosides.

Key words: stereoselective synthesis, heterocycles, medicinal chemistry, nucleosides

The preparation and functionalization of oligonucleotide analogues have attracted an increasing degree of interest because of the variety of potential applications of such compounds. Oligonucleotide analogues have been widely used, for example, in exploring the catalytic mechanisms of enzymes and ribozymes,¹ in studying physical and biological properties of nucleic acids and RNA,² in controlling gene expression,³ in identifying catalytic metal ions,⁴ and in probing hydrogen-bonding interactions.⁵ The biological, biochemical, physical, and medicinal importance of oligonucleotide analogues has fostered the development of various nucleoside modifications. In general, the two primary strategies that are used to prepare structural modifications of nucleotide analogues involve modification of the nucleobase or modification of the sugar residue, respectively. A classical method for modification of the sugar residues involves the removal or replacement of the oxygen atom in the 3'-position with a larger, more-electropositive, sulfur atom.⁶ By this approach, a variety of 3'-*S*-modified nucleosides containing diverse functionalized bases have been prepared as building blocks and intermediates for oligonucleotides. These compounds have been widely used to mimic RNA, to investigate the mechanistic properties of ribozymes, and to increase the resistance of ribozymes to degradation by nucleases.⁷ However, 3'-thio nucleoside analogues that contain inosine-derived bases have received little attention.⁸

Recently, Piccirilli and co-workers⁹ reported the synthesis and biochemical applications of 2'-*O*-methyl-3'-thioguanosine. The product was incorporated into oligo-

nucleotides to study the mechanism of a ribozyme reaction in *Tetrahymena*. Inspired by this design, we developed an efficient method for the synthesis of a new inosine-containing 2'-deoxy-3'-thionucleoside analogue **6**, together with its phosphorothioamidite **7**, as shown in Figure 1. This product can act as a general base that can pair with any of the four nucleobases¹⁰ and it can also match any the four base pairs associated with the hybridization effect in any position.¹¹ Furthermore, the design of the synthesis of **6** provides an alternative method for the synthesis of nucleoside analogues. We hope that these products will be useful as intermediates and building blocks for the preparation of other functionalized nucleosides.




Figure 1 5'-O-[[Bis(4-methoxyphenyl)(phenyl)methyl]]-2'-deoxy-3'-thioinosine **6** and its *S*-phosphorothioamidite **7**

In our synthetic route to the required compounds, the preparation of intermediate **3** (Scheme 1) through inversion of the configuration of the hydroxy group at the 3'-position of the sugar moiety is vital. According to the literature, there are several methods for realizing a configurational inversion of a 3'-hydroxy group. First, we examined the approach reported by Challa and Bruice¹² for the synthesis of *N*²-isobutyryl-2'-deoxy-*xylo*-guanosine. Treatment 2'-deoxyinosine (**1**) with benzoyl chloride in anhydrous pyridine at room temperature gave 5'-*O*-benzoyl-2'-deoxyinosine (Scheme 1, path a). Treatment of

SYNTHESIS 2013, 45, 0106–0110

Advanced online publication: 11.12.2012

DOI: 10.1055/s-0032-1317713; Art ID: SS-2012-H0579-OP


© Georg Thieme Verlag Stuttgart · New York

this product with 1.5 equivalents of triflic anhydride in dichloromethane containing 10% pyridine gave 2'-deoxy-*xylo*-inosine, which has an inverted configuration at the 3'-position. Although we obtained a small amount of this required intermediate, we did not take this route any further because of the low yields and the laborious procedures involved in chromatographic purifications.

We then tried another synthetic route developed by Piccirilli and coworkers⁹ (Scheme 1, path b). In the presence of 4-(*N,N*-dimethylamino)pyridine, the reaction of 5'-*O*-[*tert*-butyl(diphenyl)silyl]-2'-deoxyinosine with triflic chloride in dichloromethane at 0 °C gave the 3'-tri-flate intermediate. Subsequent S_N2 substitution with sodium bromide in acetone resulted in a product with an inverted configuration at the 3'-position. However, the conversion was very low, even after prolonged reaction times. This might have been due to the low reactivity and low solubility of 5'-*O*-[*tert*-butyl(diphenyl)silyl]-3'-*O*-tri-flyl-2'-deoxy-*xylo*-inosine in the reaction solvent. Finally

we opted to perform the configuration inversion at C3' by means of an oxidation–reduction sequence¹³ (Scheme 1, path c).

The complete preparation began with commercially available 2'-deoxyinosine (**1**). Although oligonucleotide syntheses involving 5'-silyl protecting groups are known, we choose the bis(4-methoxyphenyl)(phenyl)methyl (4,4'-dimethoxytrityl; Dmt) protecting group for the 5'-*O*-hydroxyl group, instead of a *tert*-butyl(dimethyl)silyl or *tert*-butyl(diphenyl)silyl group, which would have to have been deprotected by treatment with tetrabutylammonium fluoride during subsequent steps. Experiments showed protection with a Dmt group ensured regioselectivity and prevented partial deprotection during oxidation by Dess–Martin periodinane [1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1*H*)-one]. After reduction by sodium borohydride propan-2-ol, the desired intermediate product **3**, with the inverted configuration, was obtained in high yield and with high regioselectivity.



Scheme 1 Reaction conditions: (a) BzCl, py; (a') Tf₂O, py, CH₂Cl₂, then H₂O; (b) TBDPSCl, py; (b₁) TfCl, DMAP, CH₂Cl₂; (b₂) NaBr, acetone, reflux; (c) DMTCl, pyridine, ; (c') 1. Dess–Martin periodinane, CH₂Cl₂; 2. *i*-PrOH, NaBH₄, acetone, –45 °C. Dmt = 4,4'-dimethoxytrityl.

Next, we used an *O*-mesyl group as a leaving group and potassium thioacetate as a nucleophile to realize the second inversion at the 3'-position (from **4** to **5**). In this procedure, compound **3** was converted into compound **4** by treatment with mesyl chloride in pyridine. Compound **4** was treated with potassium thioacetate in *N,N*-dimethylformamide at 60 °C for 24 hours to give the thioacetate intermediate **5** (Scheme 2).

The target phosphorothioamidite **7** was efficiently obtained in two steps (Scheme 2). First, thioacetate **5** was deprotected by reduction with lithium aluminum hydride to give the sulfanyl derivative **6** in high yield (91.5%). A solution of **6** in dichloromethane was stirred with *N,N*-diisopropylethylamine and 2-cyanoethyl diisopropylamidochloridophosphite at room temperature for three hours to give the target compound **7** in an overall yield of 18.1%.

Compared with literature methods, this synthetic design has advantages of brief reaction steps, a relatively high overall yield, and regioselectivity in the configuration-inversion steps. The products should be useful as building


blocks and intermediates for the preparation of new functionalized nucleosides.

All chemicals were obtained commercially and used as received unless otherwise mentioned. DMF was dried over MgSO_4 and distilled. Pyridine was refluxed over KOH and then distilled. CH_2Cl_2 was heated with CaH_2 for 6 h, decanted, and then distilled. Solvents and liquid reagents were introduced from oven-dried microsyringes. TLC analyses were carried out on silica gel 60 F254, and spots were examined under UV radiation. Column chromatography was carried out on silica gel (200–300 mesh).

^1H and ^{13}C NMR spectra were recorded on a Bruker AM-500 spectrometer. All mass spectrometric analyses were performed on a ThermoStar mass spectrometer.

5'-*O*-[Bis(4-methoxyphenyl)(phenyl)methyl]-2'-deoxyinosine (**2**)¹⁴

A stirred soln of 2'-deoxyinosine (**1**; 0.252 g, 1.0 mmol) in anhyd pyridine (10 mL) was treated with DMTCl (0.406 g, 1.2 mmol). After 19 h, MeOH (2 mL) was added and stirring was continued for 5 min. The mixture was then transferred into CH_2Cl_2 (20 mL) and the soln was washed successively with H_2O (2×20 mL) and brine (2×20 mL) then dried (Na_2SO_4), filtered, and concentrated under vacuum. The resulting yellow oil was purified by chromatography [silica



Scheme 2 Reaction conditions: (a) DmtCl, py, r.t., 19 h (81.4%); (b) (1) Dess–Martin periodinane, CH_2Cl_2 , r.t. 3 h; (2) *i*-PrOH, NaBH_4 , acetone, -45 °C, 13 h (85.2%); (c) MsCl, *i*-PrOH, r.t., 12 h (44.0%); (d) KSac, DMF, 60 °C, 24 h (67.4%); (e) LiAlH_4 , THF–HOAc, argon, r.t. 3 h (91.5%); (f) *i*-Pr₂NP(Cl)O(CH_2)₂CN, DIPEA, CH_2Cl_2 , r.t., 3 h (95.2%).

gel, CH₂Cl₂–EtOH (20:1)] to give a white solid; yield: 0.451 (81.4%).

¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.37 (s, 1 H), 8.19 (s, 1 H), 7.99 (s, 1 H), 7.34–6.77 (m, 13 H), 6.34 (dd, *J*₁ = 4.0 Hz, *J*₂ = 12 Hz, 1 H), 5.38 (d, *J* = 4 Hz, 1 H), 4.42 (m, 1 H), 3.97 (dd, *J*₁ = 4 Hz, *J*₂ = 12 Hz, 1 H), 3.72 (s, 6 H), 3.15 (dd, *J*₁ = 4.0 Hz, *J*₂ = 12 Hz, 2 H), 2.77 (m, 1 H), 2.34 (m, 1 H).

¹³C NMR (100 MHz, DMSO-*d*₆): δ = 157.94, 156.62, 147.90, 145.50, 144.75, 138.73, 135.47, 129.60, 127.70, 127.59, 126.62, 124.53, 113.01, 85.80, 85.35, 83.49, 70.41, 63.88, 56.06, 54.95.

MS (ESI): *m/z* [M + H]⁺ calcd for C₃₁H₃₁N₄O₆: 555.2; found: 555.3.

5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-2'-deoxy-xylo-ino-sine (3)¹⁵

Product **2** (0.554 g, 1.0 mmol) was added to a chilled stirred soln of Dess–Martin periodinane (0.640 g, 1.5 mmol) in anhyd CH₂Cl₂ (8 mL) at 0 °C, and the soln was stirred at 0 °C for 1 h and then at r.t. for 4 h. *i*-PrOH (8 mL) was added and the resulting white slurry was cooled to –45 °C. After 20 min, freshly powdered NaBH₄ (76 mg, 2.0 mmol) was added and the mixture was stirred for 12 h at –45 °C. Acetone (8 mL) was added and the mixture was allowed to warm to r.t., diluted with CH₂Cl₂ (20 mL), and washed sequentially with aq NaHCO₃ (2 × 20 mL), H₂O (2 × 20 mL), and brine (2 × 20 mL). The organic layer was separated, dried (Na₂SO₄), filtered, and concentrated under vacuum. The residue was purified by chromatography [silica gel, CH₂Cl₂–EtOH (15:1)] to give a white foamy solid; yield: 0.472 g (85.2%).

¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.39 (s, 1 H), 8.14 (s, 1 H), 8.09 (d, *J* = 4 Hz, 1 H), 7.41–6.77 (m, 13 H), 6.33 (dd, *J*₁ = 4.0 Hz, *J*₂ = 12 Hz, 1 H), 5.42 (d, *J* = 4 Hz, 1 H), 4.33 (m, 1 H), 4.21 (dd, *J*₁ = 4 Hz, *J*₂ = 12 Hz, 1 H), 3.73 (s, 3 H), 3.72 (s, 3 H), 3.18 (dd, *J*₁ = 4.0 Hz, *J*₂ = 12 Hz, 2 H), 2.72 (m, 1 H), 2.26 (m, 1 H).

¹³C NMR (100 MHz, DMSO-*d*₆): δ = 157.96, 156.60, 147.73, 145.76, 144.98, 138.78, 135.68, 135.54, 129.71, 127.68, 126.56, 124.02, 113.01, 85.42, 83.93, 83.01, 69.28, 63.14, 54.94, 40.82.

MS (ESI): *m/z* [M + H]⁺ calcd for C₃₁H₃₁N₄O₆: 555.2; found: 555.3.

5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-mesyl-2'-de-oxynosine (4)¹⁶

A soln of MsCl (77 μL, 1.0 mmol) in pyridine (2 mL) was added dropwise to a stirred soln of compound **3** (0.277 g, 0.5 mmol) in anhyd pyridine (4 mL) at 0 °C. The cooling bath was removed and the mixture was stirred for 12 h at r.t. The mixture was then poured into ice–water and stirred for another 10 min. The resulting mixture was diluted with CH₂Cl₂ (20 mL) and the organic layer was separated, washed with aq NaHCO₃ (2 × 20 mL), H₂O (2 × 20 mL), and brine (2 × 20 mL) then dried (Na₂SO₄), filtered, and concentrated under vacuum. The crude product was purified by chromatography [silica gel, CH₂Cl₂–EtOH (20:1)] to give a white foamy solid; yield: 0.139 g (44.0%).

¹H NMR (400 MHz, CDCl₃): δ = 11.91 (s, 1 H), 8.02 (s, 1 H), 7.99 (s, 1 H), 7.44–6.82 (m, 13 H), 6.43 (m, 1 H), 5.46 (m, 1 H), 4.37 (m, 1 H), 3.80 (s, 6 H), 3.66 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 3.36 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 2.93 (m, 2 H), 2.74 (s, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 153.44, 153.24, 142.34, 140.10, 139.41, 135.22, 130.63, 130.52, 124.79, 122.86, 122.62, 121.61, 119.99, 107.91, 81.36, 79.11, 78.85, 65.71, 57.10, 49.97, 35.83, 24.47.

MS (ESI): *m/z* [M + H]⁺ calcd for C₃₂H₃₃N₄O₈S: 633.2; found: 633.3.

5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-2-deoxy-3'-thio-inosyl 3'-S-Acetate (5)¹⁶

KSAc (70.3 mg, 0.617 mmol) was added to a colorless soln of compound **4** (0.130 g, 0.21 mmol) in anhyd DMF (8 mL), and the mix-

ture was stirred at 60 °C for 24 h under argon. The mixture was then transferred into CH₂Cl₂ (10 mL) and the soln was washed with aq NaHCO₃ (2 × 20 mL), H₂O (2 × 20 mL), and brine (2 × 20 mL). The organic layer was separated, dried (Na₂SO₄), filtered, concentrated, and co-evaporated with toluene to remove the DMF. The residual oil was purified by chromatography [silica gel, CH₂Cl₂–EtOH (15:1)] to give a white foamy solid; yield: 86.6 mg (67.4%).

¹H NMR (400 MHz, CDCl₃): δ = 12.13 (s, 1 H), 8.07 (s, 1 H), 7.99 (s, 1 H), 7.44–6.77 (m, 13 H), 6.33 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 4.27 (m, 1 H), 4.17 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1 H), 3.78 (s, 6 H), 3.40 (d, *J* = 4.0 Hz, 2 H), 3.03 (m, 1 H), 2.56 (m, 1 H), 2.34 (s, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 194.04, 159.21, 158.53, 148.42, 144.99, 144.39, 139.48, 138.39, 135.57, 130.09, 129.15, 128.15, 127.84, 126.93, 125.14, 113.17, 86.64, 84.48, 84.02, 63.29, 55.25, 40.80, 39.61, 30.62.

MS (ESI): *m/z* [M + H]⁺ calcd for C₃₃H₃₃N₄O₆S: 613.2; found: 613.3.

5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-2-deoxy-3'-thio-inosine (6)¹⁶

A suspension of LiAlH₄ (15.2 mg, 0.4 mmol) in anhyd THF (5 mL) was cooled to 0 °C and then a soln of compound **5** (61.2 mg, 0.1 mmol) in THF (5 mL) was added dropwise under argon. The mixture was stirred for 4 h at r.t. then treated with 1 M aq HOAc (2 × 20 mL). CH₂Cl₂ (10 mL) was added and the organic layer was separated, washed with brine (2 × 20 mL), dried (Na₂SO₄), filtered, and concentrated under vacuum. The residue was purified by chromatography [silica gel, CH₂Cl₂–EtOH (12:1)] to give a white foamy solid; yield: 52.2 mg (91.5%).

¹H NMR (400 MHz, CDCl₃): δ = 12.62 (s, 1 H), 8.10 (s, 1 H), 8.04 (s, 1 H), 7.43–6.80 (m, 13 H), 6.32 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 4.00 (m, 1 H), 3.78 (s, 6 H), 3.75–3.70 (m, 1 H), 3.53 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 3.42 (dd, *J*₁ = 4.0 Hz, *J*₂ = 8 Hz, 1 H), 2.93 (m, 1 H), 2.49 (m, 1 H), 1.65 (d, *J* = 8 Hz, 1 H).

¹³C NMR (100 MHz, CDCl₃): δ = 158.21, 157.53, 147.16, 143.99, 143.38, 137.59, 134.52, 129.01, 127.07, 126.93, 125.94, 124.21, 112.21, 87.39, 85.61, 83.15, 60.75, 54.22, 41.68, 34.01.

MS (ESI): *m/z* [M + H]⁺ calcd for C₃₁H₃₀N₄O₅S: 571.2; found: 571.3.

S-[5'-O-[Bis(4-methoxyphenyl)(phenyl)methyl]-2-deoxy-3'-thioinosinyl] O-(2-Cyanoethyl) Diisopropylamidothiophosphite (7)

DIPEA (68.4 μL, 0.40 mmol) and *i*-Pr₂NP(Cl)(CH₂)₂CN (31.8 μL, 0.14 mmol) were added to a stirred soln of compound **6** (40 mg, 0.070 mmol) in anhyd CH₂Cl₂ (5 mL), and the mixture was stirred at r.t. for 3 h. The mixture was then diluted with CH₂Cl₂ (10 mL) and washed successively with H₂O (2 × 20 mL) and brine (2 × 20 mL) then dried (Na₂SO₄), filtered, and concentrated under vacuum. The residue was purified by chromatography (silica gel, 0.5% Et₃N in 5% EtOH–CH₂Cl₂) to give a white solid; yield: 51.3 mg (95.2% yield).

¹H NMR (400 MHz, CDCl₃): δ = 13.17 (s, 1 H), 8.15–8.06 (s, 2 H), 7.40–6.76 (m, 13 H), 6.39–6.29 (m, 1 H), 4.54–4.44 (m, 1 H), 4.24–4.17 (m, 1 H), 3.76 (s, 6 H), 3.66–3.52 (m, 4 H), 3.48–3.36 (m, 2 H), 3.04–2.95 (m, 1 H), 2.75–2.66 (m, 1 H), 2.60–2.55 (m, 1 H), 2.45–2.41 (m, 1 H), 1.28–1.02 (m, 12 H).

¹³C NMR (100 MHz, CDCl₃): δ = 158.74, 158.54, 148.60, 145.28, 144.47, 138.37, 135.61, 130.06, 128.14, 127.87, 126.94, 125.13, 117.48, 113.15, 86.49, 84.57, 73.47, 63.33, 55.35, 55.25, 45.92, 43.27, 29.69, 24.62, 20.19.

³¹P NMR (162 MHz, CDCl₃): δ = 165.42, 165.05.

HRMS: *m/z* [M]⁺ calculated for C₄₀H₄₇N₆O₆PS: 770.3015; found: 770.3038.

Acknowledgment

We thank the National Nature Science Foundation of China (No. 20702014) and the Fundamental Research Funds for the Central Universities of China (WK1114053) for their financial support. We are grateful to Professor H. Tian of the East China University of Science and Technology for his valuable support for this project.

Supporting Information for this article is available online at <http://www.thieme-connect.com/ejournals/toc/synthesis>.

References

- (1) Piccirilli, J. A.; Vyle, J. S.; Caruthers, M. H.; Cech, T. R. *Nature (London)* **1993**, *361*, 85.
- (2) (a) Thibaudeau, C.; Plavec, J.; Garg, N.; Papchikhin, A.; Chattopadhyaya, J. *J. Am. Chem. Soc.* **1994**, *116*, 4038. (b) Plavec, J.; Thibaudeau, C.; Chattopadhyaya, J. *J. Am. Chem. Soc.* **1994**, *116*, 6558.
- (3) (a) Liu, X.; Reese, C. B. *Tetrahedron Lett.* **1996**, *37*, 925. (b) Weinstein, L. B.; Earnshaw, D. J.; Cosstick, R.; Cech, T. R. *J. Am. Chem. Soc.* **1996**, *118*, 10341.
- (4) Gordon, P. M.; Sontheimer, E. J.; Piccirilli, J. A. *RNA* **2000**, *6*, 199.
- (5) Szewczak, A. A.; Kosek, A. B.; Piccirilli, J. A.; Strobel, S. A. *Biochemistry* **2002**, *41*, 2516.
- (6) (a) Butora, G.; Kenski, D. M.; Cooper, A. J.; Fu, W.; Qi, N.; Li, J. J.; Flanagan, W. M.; Davies, I. W. *J. Am. Chem. Soc.* **2011**, *133*, 16766. (b) Kannan, A.; Burrows, C. J. *J. Org. Chem.* **2010**, *76*, 720. (c) Wunderlich, C. H.; Spitzer, R.; Santner, T.; Fauster, K.; Tollinger, M.; Kreutz, C. *J. Am. Chem. Soc.* **2012**, *134*, 7558.
- (7) Beevers, A. P. G.; Fettes, K. J.; O'Neil, I. A.; Roberts, S. M.; Arnold, J. R. P.; Cosstick, R.; Fisher, J. *Chem. Commun. (Cambridge)* **2002**, 1458.
- (8) (a) Sabbagh, G.; Fettes, K. J.; Gosain, R.; O'Neil, I. A.; Cosstick, R. *Nucleic Acids Res.* **2004**, *32*, 495. (b) Ariza, X.; Bou, V.; Vilarrasa, J. *J. Am. Chem. Soc.* **1995**, *117*, 3665. (c) Terrazas, M.; Ariza, X.; Farràs, J.; Guisado-Yang, J. M.; Vilarrasa, J. *J. Org. Chem.* **2004**, *69*, 5473. (d) Terrazas, M.; Ariza, X.; Vilarrasa, J. *Org. Lett.* **2005**, *7*, 2477.
- (9) Lu, J.; Li, N.-S.; Sengupta, R. N.; Piccirilli, J. A. *Bioorg. Med. Chem.* **2008**, *16*, 5754.
- (10) (a) Martin, F. H.; Castro, M. M.; Aboul-ela, F.; Tinoco, I. *Nucleic Acids Res.* **1985**, *13*, 8927. (b) Kawase, Y.; Iwai, S.; Inoue, H.; Miura, K.; Ohtsuka, E. *Nucleic Acids Res.* **1986**, *14*, 7727. (c) Ohtsuka, E.; Matsuki, S.; Ikehara, M.; Takahashi, Y.; Matsubara, K. *J. Biol. Chem.* **1985**, *260*, 2605.
- (11) Case-Green, S. C.; Southern, E. M. *Nucleic Acids Res.* **1994**, *22*, 131.
- (12) Challa, H.; Bruice, T. C. *Bioorg. Med. Chem.* **2004**, *12*, 1475.
- (13) Hansske, F.; Madej, D.; Robins, M. J. *Tetrahedron* **1984**, *40*, 125.
- (14) (a) Bae, S.; Lakshman, M. K. *J. Am. Chem. Soc.* **2007**, *129*, 782. (b) Seela, F.; Kaiser, K. *Nucleic Acids Res.* **1986**, *14*, 1825. (c) Hansen, A. S.; Thalhammer, A.; El-Sagheer, A. H.; Brown, T.; Schofield, C. J. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1181. (d) Lakshman, M. K.; Bae, S. WO 2008045535 **2008**; *Chem. Abstr.* **2008**, *148*, 449867.
- (15) Eisenhuth, R.; Richert, C. *J. Org. Chem.* **2008**, *74*, 26.
- (16) Xiao, P.; Bai, Y.; Chen, J.; Lu, Z. CN 102180926 **2011**; *Chem. Abstr.* **2011**, *155*, 484417.